Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases. 31720935 2020
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker disease BEFREE Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT Imaging. 31714276 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. 29995686 2020
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker disease BEFREE Herein, we present the case of a 49-year-old man with pancreatoblastoma and liver metastasis who underwent preoperative multimodal imaging, in which F-FDG PET/CT showed a markedly increased F-FDG uptake in the metastatic lesion and a slightly increased uptake in the primary lesion. 31274558 2020
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker disease BEFREE FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis. 31612350 2020
Entrez Id: 7852
Gene Symbol: CXCR4
CXCR4
0.100 AlteredExpression disease BEFREE The relationship between these two signaling pathways remains to be delineated in liver metastasis of colon cancer.<b>Methods</b>: Immunohistochemistry was employed to investigate CXCR4 expression in 45 human specimens of primary colorectal cancer (CRC) and liver metastasis. 31825725 2020
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker disease BEFREE Evaluation of [<sup>18</sup>F]FDG/[<sup>18</sup>F]FLT/[<sup>18</sup>F]FMISO-based micro-positron emission tomography in detection of liver metastasis in human colorectal cancer. 31330410 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE Left-sided tumors with wild-type KRAS had greater proportion of liver metastasis (78.6% versus 53.5%, P = 0.00), whereas those with mutant KRAS had greater proportion of lung metastasis (23.3% versus 8.7%, P = 0.02). 30737098 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE In the six locally advanced cases, KRAS mutation appeared concurrently with liver metastasis. 31746520 2020
Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
0.100 Biomarker disease BEFREE Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis. 30941323 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE When treating hormone receptor-positive/HER2-negative MBC patients with endocrine therapy, it is important to differentiate patients with lung metastases from those with liver metastases. 31373147 2019
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.100 Biomarker disease BEFREE PRRX2 and β-catenin in patients with the liver metastases of colon cancer was detected by immunochemistry. 31471104 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE TP53 mutations were studied by Sanger sequencing in the remaining patients; the number of patients with TP53 mutations in metastatic tumors was significantly higher among those with liver metastasis (86.5%, 32/37) versus those without liver metastasis (40.5%; 15/37; P < 0.0001). 30703342 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study. 31839435 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. 31183866 2019
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.100 AlteredExpression disease BEFREE ECOG (Eastern Cooperative Oncology Group) performance scores, CEA levels, CA19-9 levels, hemoglobin levels, lactate dehydrogenase levels, and liver metastasis ratios varied significantly between the low and high AGR groups (p < .05). 29785861 2019
Entrez Id: 5670
Gene Symbol: PSG2
PSG2
0.100 AlteredExpression disease BEFREE A decreased overall survival was significantly associated with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992). 31542818 2019
Entrez Id: 7852
Gene Symbol: CXCR4
CXCR4
0.100 Biomarker disease BEFREE The Diagnostic Value of Chemokine/Chemokine Receptor Pairs in Hepatocellular Carcinoma and Colorectal Liver Metastasis. 30633620 2019
Entrez Id: 960
Gene Symbol: CD44
CD44
0.100 AlteredExpression disease BEFREE After HA receptor (CD44)-mediated cellular uptake of the HTsRP-NC by the liver cancer cells, functional expression of AKT siRNA leads to the suppression of metastatic liver cancer growth in a colorectal liver metastasis (CLM) murine model. 30399434 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update. 31426677 2019
Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
0.100 AlteredExpression disease BEFREE ECOG (Eastern Cooperative Oncology Group) performance scores, CEA levels, CA19-9 levels, hemoglobin levels, lactate dehydrogenase levels, and liver metastasis ratios varied significantly between the low and high AGR groups (p < .05). 29785861 2019
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.100 Biomarker disease BEFREE In conclusion, targeting CBP/β-catenin, combined with PD-1/PD-L1 immune checkpoint blockade, shows potential as a new therapeutic strategy for treating liver metastasis during colon cancer. 31105882 2019
Entrez Id: 5670
Gene Symbol: PSG2
PSG2
0.100 AlteredExpression disease BEFREE ECOG (Eastern Cooperative Oncology Group) performance scores, CEA levels, CA19-9 levels, hemoglobin levels, lactate dehydrogenase levels, and liver metastasis ratios varied significantly between the low and high AGR groups (p < .05). 29785861 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Multivariate analysis identified ECOG performance status, EGFR mutation/ALK rearrangement status, liver metastasis and PD-L1 proportion as independent predictors of OS. 30911841 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Interestingly, the PD-L1 staining pattern remained similar between primary tumors and corresponding liver metastases. 30389315 2019